BioInvent International AB: Interim report January-June 2021
LUND, Sweden, Aug. 26, 2021 /PRNewswire/ -- "We are very pleased we have reached a second collaboration with MSD (Merck) that supports the expansion of the ongoing clinical trial program with our anti-TNFR2 antibody BI-1808. We are excited about the potential synergistic activity of BI-1808 in combination with pembrolizumab and this agreement supports the strong interest elicited by our broadening pipeline of anti-cancer antibodies."- CEO Martin Welschof on the new agreement with Merck.
Events in the quarter
BioInvent received IND approval for Phase 1/2a trial of anti-TNFR2 antibody BI-1808.
BioInvent and Transgene received IND approval from the U.S. FDA for BT-001, a novel oncolytic virus delivering an anti-CTLA-4 antibody for the treatment of solid tumors.
BioInvent received notice of allowance in China for the anti-Fc?RllB antibody BI-1206 patent.
Events after the period
(R) BioInvent announced a second clinical trial collaboration and supply agreement with Merck to evaluate BI-1808 in combination with Keytruda® (pembrolizumab) in patients with advanced solid tumors.
Financial information
SECOND QUARTER 2021
Net sales SEK 5.3 (15.6) million.
Loss after tax SEK -57.3 (-39.3) million.
Loss after tax per share before and after dilution SEK -0.98 (-2.00).
Cash flow from operating activities and investment activities SEK -65.9 (-28.4) million.
JANUARY ? JUNE 2021
Net sales SEK 11.5 (32.4) million.
Loss after tax SEK -137.1 (-72.0) million.
Loss after tax per share before and after dilution SEK -2.75 (-3.50).
Cash flow from operating activities and investment activities SEK -117.4 (-63.9) million.
Liquid funds as of June 30, 2021: SEK 1,509.7 (182.3) million.
This information is such information as BioInvent International AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 8:00 a.m. CEST on August 26, 2021.
For further information, please contact: Cecilia Hofvander, Investor Relations +46 (0)46 286 85 50 [email protected]
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.Ttm technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.
Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology industry veteran Arlene Morris to its Board of Directors. Ms. Morris has extensive experience in the pharmaceutical...
Guardant Health, Inc. , a leading precision oncology company, today announced its achievement of surpassing a significant milestone of 500 peer-reviewed publications featuring its technology in esteemed scientific journals. This milestone highlights...
Celerion, a leading clinical research organization, specializing in early clinical research and bioanalytical services, today announced the appointment of Jo Goodman as vice president of bioanalytical services in its Lincoln, Nebraska, laboratory....
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following investor conferences in May:
Citizens JMP...
Vivodyne, a pioneering biotech company that grows and tests on lab-grown human tissues to accelerate therapeutics discovery and development, today announced the appointment of Julie O'Shaughnessy as Chief Operating Officer. In her new role, Julie...
iECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with significant unmet need, announced today that it has received Fast...